NO20080051L - Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme - Google Patents

Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme

Info

Publication number
NO20080051L
NO20080051L NO20080051A NO20080051A NO20080051L NO 20080051 L NO20080051 L NO 20080051L NO 20080051 A NO20080051 A NO 20080051A NO 20080051 A NO20080051 A NO 20080051A NO 20080051 L NO20080051 L NO 20080051L
Authority
NO
Norway
Prior art keywords
piperazinyl
methoxyphenyl
propoxy
dichloro
methoxy
Prior art date
Application number
NO20080051A
Other languages
English (en)
Norwegian (no)
Inventor
Gregg Brian Feigelson
Henry Lee Strong
Hong Wen
Marc Sadler Tesconi
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=37103295&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20080051(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of NO20080051L publication Critical patent/NO20080051L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Medicinal Preparation (AREA)
NO20080051A 2005-07-01 2008-01-04 Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme NO20080051L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69638105P 2005-07-01 2005-07-01
PCT/US2006/025160 WO2007005462A1 (en) 2005-07-01 2006-06-28 Crystalline forms of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1-piperazinyl)propoxy]-3-quinolinecarb-onitrile and methods of preparing the same

Publications (1)

Publication Number Publication Date
NO20080051L true NO20080051L (no) 2008-01-29

Family

ID=37103295

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20080051A NO20080051L (no) 2005-07-01 2008-01-04 Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme

Country Status (25)

Country Link
US (2) US7767678B2 (pl)
EP (1) EP1902029B2 (pl)
JP (1) JP2009500332A (pl)
KR (1) KR20080028386A (pl)
CN (1) CN101248047A (pl)
AR (1) AR054505A1 (pl)
AU (1) AU2006266045A1 (pl)
BR (1) BRPI0613574A2 (pl)
CA (1) CA2613053C (pl)
CR (1) CR9596A (pl)
DK (1) DK1902029T4 (pl)
EC (1) ECSP078063A (pl)
ES (1) ES2449197T5 (pl)
GT (1) GT200600282A (pl)
HK (1) HK1114614A1 (pl)
IL (1) IL188483A0 (pl)
MX (1) MX2008000384A (pl)
NO (1) NO20080051L (pl)
PA (1) PA8685101A1 (pl)
PE (1) PE20070190A1 (pl)
PL (1) PL1902029T5 (pl)
PT (1) PT1902029E (pl)
RU (1) RU2007148072A (pl)
TW (1) TW200740797A (pl)
WO (1) WO2007005462A1 (pl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2766067A1 (en) * 2009-07-02 2011-01-06 Wyeth Llc 3-cyanoquinoline tablet formulations and uses thereof
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
CN104447541A (zh) * 2013-09-16 2015-03-25 天津市汉康医药生物技术有限公司 博舒替尼化合物
US9776970B2 (en) 2014-02-20 2017-10-03 Apotex Inc. Bosutinib forms and preparation methods thereof
WO2015149727A1 (en) 2014-04-02 2015-10-08 Zentiva, K.S. Novel solid phases of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methyl-1 -piperazinyl)propoxy]-3-quinolinecarbonitrile
CN105384686B (zh) * 2014-09-04 2019-07-26 连云港润众制药有限公司 一种博舒替尼结晶方法
WO2016034150A1 (zh) * 2014-09-04 2016-03-10 正大天晴药业集团股份有限公司 博舒替尼及其结晶的制备方法
WO2017029584A1 (en) * 2015-08-19 2017-02-23 Sun Pharmaceutical Industries Limited Amorphous form of bosutinib
WO2017134679A1 (en) * 2016-02-03 2017-08-10 Msn Laboratories Private Limited Novel crystalline polymorphs of 4-[(2.4-dichioro-5-methoxvphenvl)aniinol- 6-methoxv-7-13-(4-methyl-l-piperazinvl)propoxvl-3-quinolinecarbonitrile and process for preparation thereof
WO2017145089A1 (en) * 2016-02-23 2017-08-31 Sun Pharmaceutical Industries Limited Crystalline form x of bosutinib
CN105646345A (zh) * 2016-03-16 2016-06-08 浙江海正药业股份有限公司 博舒替尼的新晶型及其制备方法
CN106187886B (zh) * 2016-07-06 2019-04-16 山东创新药物研发有限公司 一种制备高纯度伯舒替尼一水合物的方法
JOP20190144A1 (ar) 2016-12-16 2019-06-16 Janssen Pharmaceutica Nv إيميدازو بيرولو بيريدين كمثبطات لعائلة jak الخاصة بإنزيمات الكيناز
CN110317168A (zh) * 2018-03-30 2019-10-11 正大天晴药业集团股份有限公司 一种博舒替尼的纯化方法
TW202016110A (zh) 2018-06-15 2020-05-01 比利時商健生藥品公司 Ｊａｋ激酶家族之小分子抑制劑
EP3953450A1 (en) 2019-04-09 2022-02-16 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
CN112321505B (zh) * 2019-10-25 2022-08-23 杭州中美华东制药有限公司 一种伯舒替尼晶型及其制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US6432979B1 (en) * 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
UA77200C2 (en) * 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
TWI275390B (en) * 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) * 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
JP2007502819A (ja) * 2003-08-19 2007-02-15 ワイス・ホールディングズ・コーポレイション ４−アミノ−３−キノリンカルボニトリルの調製方法
WO2005065074A2 (en) * 2003-09-09 2005-07-21 Temple University Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
WO2005047259A1 (en) * 2003-11-06 2005-05-26 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
US7910211B2 (en) * 2005-06-20 2011-03-22 E.I. Du Pont De Nemours And Company Process for the production of multi-layer coatings
RU2007143434A (ru) 2005-06-24 2009-07-27 Вайет (Us) 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний
US8520232B2 (en) * 2006-03-31 2013-08-27 Konica Minolta Laboratory U.S.A., Inc. Print job analyzing method and apparatus with print device recommendation functions

Also Published As

Publication number Publication date
RU2007148072A (ru) 2009-08-10
PL1902029T3 (pl) 2014-08-29
CR9596A (es) 2008-03-06
KR20080028386A (ko) 2008-03-31
CN101248047A (zh) 2008-08-20
US20100324066A1 (en) 2010-12-23
TW200740797A (en) 2007-11-01
ECSP078063A (es) 2008-01-23
JP2009500332A (ja) 2009-01-08
WO2007005462A1 (en) 2007-01-11
ES2449197T5 (es) 2022-04-28
DK1902029T3 (en) 2014-02-17
EP1902029B2 (en) 2022-02-16
CA2613053A1 (en) 2007-01-11
PT1902029E (pt) 2014-03-05
AU2006266045A1 (en) 2007-01-11
PE20070190A1 (es) 2007-03-20
PL1902029T5 (pl) 2022-08-29
PA8685101A1 (es) 2007-01-17
ES2449197T3 (es) 2014-03-18
EP1902029A1 (en) 2008-03-26
US8445496B2 (en) 2013-05-21
IL188483A0 (en) 2008-04-13
BRPI0613574A2 (pt) 2016-11-16
DK1902029T4 (da) 2022-02-28
US20070015767A1 (en) 2007-01-18
GT200600282A (es) 2007-02-14
US7767678B2 (en) 2010-08-03
HK1114614A1 (en) 2008-11-07
EP1902029B1 (en) 2014-01-08
MX2008000384A (es) 2008-03-07
CA2613053C (en) 2015-11-24
AR054505A1 (es) 2007-06-27

Similar Documents

Publication Publication Date Title
NO20080051L (no) Krystallinske former av 4-((2,4-diklor-5-metoksyfenyl)amino)-6-metoksy-7--[3-(4-metyl-1-piperazinyl)propoksy]3-kinolinkarbonitril og metoder for fremstilling av samme
NO20080820L (no) Krystallinske former for 4-metyl-N-[3-(4-metylimidazol-1-yl)-5-trifluormetylfenyl]-3-(4-pyridin-3-ylpyrimidin-2-ylamino)benzamid
NO20076066L (no) Oksadiazolderivater som DGAT-inhibitorer
NO20082481L (no) Nye 2-aminoheterosykluser som er nyttige ved behandling av ABETA-relaterte patologier
NO20063501L (no) Kinolinintermediater av reseptor-Tyrosin-Kinase-inhibitorer og deres syntese
NO20090755L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
MX2010006179A (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
NO20071320L (no) Pyrazolsubstituerte aminoheteroarylforbindelser som protein kinase inhibitorer.
NO20080394L (no) N-(arylalkyl)-1H-pyrrolopyridin-2-karboksamidderivater, fremstilling og anvendelse derav
NO20082673L (no) Nye 2-amino-imidazol-4-on forbindelser og deres anvendelse i fremstilling av et medikament som skal brukes til behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerasjon og demens
NO20090166L (no) Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens
NO20074275L (no) 2- (4-okso-4H-kinazolin-3-yl) acetamider og deres anvendelse som Vasopressin-V3-antagonister
NO20081454L (no) Met-kinaseinhibitorer
HK1135103A1 (en) Dihydropyridine derivatives useful as protein kinase inhibitors
MX2010005556A (es) Procedimiento para la fabricacion de un derivado de indolinona.
NO20083427L (no) Cystoksiske midler omfattende nye tomaymycinderivater og deres terapeutiske anvendelse
NO20084924L (no) N-(2-thiazolyl)-amid derivater som GSK-3 inhibitorer
EA200970090A1 (ru) Модуляторы метаболизма и лечение связанных с ним расстройств
NO20061640L (no) Hurtig opplosningspreparat av en kalsiumreseptiraktiv forbindelse
NO20062021L (no) Omleirede pentanoler, fremgangsmpte for fremstilling av dette, og deres anvendelse som antiflogistika
NO20082209L (no) Homo- og heterocykliske forbindelser anvendbare som CETP-inhibitorer
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
NO20083065L (no) Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander
NO20091463L (no) Heterocyklisk deriverte metalloproteaseinhibitorer
NO20074188L (no) Prosess for fremstilling av montelukast og mellomprodukter for det

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application